Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2578-2584

  Brouckaert, O ^a   Laenen, A ^b   Vanderhaegen, J ^a   Wildiers, H ^a   Leunen, K ^a   Amant, F ^a   Berteloot, P ^a   Smeets, A ^a   Paridaens, R ^a   Christiaens, M R ^a   Floris, G ^a   Moerman, P ^a   Van Limbergen, E ^a   Peeters, S ^a   Weltens, C ^a   Vergote, I ^a   Neven, P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Breast cancer; ER; HER 2; PR; Subtypes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; BREAST CANCER SPECIFIC SURVIVAL; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HOSPITALIZATION; HUMANS; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867131355     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds062     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
2. Surveillance Epidemiology and End Results. Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site, Race and Sex: Cancer Statistics Review 1975-2000. http://seer.cancer.gov/csr/1975_2000/results_merged/topic_lifetime_risk. pdf (October 2011, date last accessed).
3. UpToDate, Inc. Epidemiology and Risk Factors for Breast Cancer. http://www. uptodate.com/contents/epidemiology-and-risk-factors-for-breast-cancer? source=see_link (October 2011, date last accessed).
4. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 6797: 747-752.
5. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 19: 10869-10874.
6. Foekens JA, Atkins D, Zhang Y et al. Multicenter validation of a gene expressionbased prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006; 11: 1665-1671.
7. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 6871: 530-536.
8. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 9460: 671-679.
9. Zhang Y, Sieuwerts AM, McGreevy M et al. The 76-gene signature defines highrisk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 2009; 2: 303-309.
10. Desmedt C, Piette F, Loi S et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007; 11: 3207-3214.
11. Weigelt B, Mackay A, A'Hern R et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010; 4: 339-349.
12. Sorlie T, Wang Y, Xiao C et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006; 7: 127.
13. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 14: 8418-8423.
14. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010; 2: 263-280.
15. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 15: 2568-2581.
16. Kaklamani V. A genetic signature can predict prognosis and response to therapy in breast cancer: oncotype DX. Expert Rev Mol Diagn 2006; 6: 803-809.
17. Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 3: R25.
18. Kelly CM, Krishnamurthy S, Bianchini G et al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 2010; 22: 5161-5167.
19. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 18: 10393-10398.
20. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5(1): 5-23.
21. Rakha EA, Ellis IO. Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Adv Anat Pathol 2011; 18(4): 255-267.
22. Mook S, Van't Veer LJ, Rutgers EJ et al. Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics 2007; 4(3): 147-155.
23. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98(4): 262-272.
24. Loi S, Haibe-Kains B, Desmedt C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25(10): 1239-1246.
25. Symmans WF, Hatzis C, Liedtke C et al. Use of genomic grade index (GGI) to predict pathologic response to preoperative chemotherapy in breast cancer. J Clin Oncol 2008; 26 (Suppl): (Abstr 541). http://meeting.ascopubs.org/cgi/ content/abstract/26/15_suppl/541.
26. Rakha EA, Reis-Filho JS, Baehner F et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010; 4: 207.
27. Neven P, Van Belle V, Brouckaert O et al. Are gene signatures better than traditional clinical factors?. Lancet Oncol 2008; 9(3): 197-198.
28. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
29. Nguyen PL, Taghian AG, Katz MS et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008; 26(14): 2373-2378.
30. Brouckaert O, Pintens S, Van Belle V et al. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Breast Cancer Res Treat 2009; 115(2): 349-358.
31. Ciocca DR, Gago FE, Fanelli MA et al. Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: clinical implications. J Steroid Biochem Mol Biol 2006; 102(1-5): 32-40.
32. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295(21): 2492-2502.
33. Gabos Z, Thoms J, Ghosh S et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat 2010; 124(1): 187-194.
34. Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14(5): 1368-1376.
35. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101(10): 736-750.
36. Cuzick J, Dowsett M, Wale C et al. Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score-results from Trans ATAC. Cancer Res 2009; 69 Suppl 24 (Abstr 74). http://breast-cancer-research.com/content/pdf/bcr2607.pdf.
37. Dawood S, Hu R, Homes MD et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 2011; 126(1): 185-192.
38. Nielsen TO, Parker JS, Leung S et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16(21): 5222-5232.
39. Voduc KD, Cheang MCU, Tyldesley S et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28(10): 1684-1691.
40. Park S, Koo JS, Kim MS et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 2012; 21(1): 50-57.